KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShort-Term Debt repayments
Ratios

Pfizer (PFE) Other Gross PP&E Adjustments (2016 - 2025)

Pfizer (PFE) has disclosed Other Gross PP&E Adjustments for 17 consecutive years, with $34.5 billion as the latest value for Q4 2025.

  • On a quarterly basis, Other Gross PP&E Adjustments rose 5.84% to $34.5 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $34.5 billion, a 5.84% increase, with the full-year FY2025 number at $34.5 billion, up 5.84% from a year prior.
  • Other Gross PP&E Adjustments was $34.5 billion for Q4 2025 at Pfizer, up from $32.6 billion in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $34.5 billion in Q4 2025 to a low of $27.1 billion in Q4 2021.
  • A 5-year average of $30.9 billion and a median of $32.1 billion in 2023 define the central range for Other Gross PP&E Adjustments.
  • Peak YoY movement for Other Gross PP&E Adjustments: increased 0.36% in 2021, then grew 12.71% in 2023.
  • Pfizer's Other Gross PP&E Adjustments stood at $27.1 billion in 2021, then increased by 4.9% to $28.4 billion in 2022, then grew by 12.71% to $32.1 billion in 2023, then increased by 1.64% to $32.6 billion in 2024, then rose by 5.84% to $34.5 billion in 2025.
  • Per Business Quant, the three most recent readings for PFE's Other Gross PP&E Adjustments are $34.5 billion (Q4 2025), $32.6 billion (Q4 2024), and $32.1 billion (Q4 2023).